Developing therapies for treatment-resistant prostate cancer
In a recent trial, nine patients whose tumors were resistant to androgen-blocking therapy continued that therapy but were also given a CD105 inhibitor called carotuximab. Forty percent of those patients experienced progression-free survival, based on radiographic imaging
Materials provided by Cedars-Sinai Medical Center. Note: Content may be edited for style and length.
Source link aaaaa